A degraded semaglutide molecule cannot bind to GLP-1 receptors properly, which means reduced efficacy or no efficacy at all
May your vials stay potent, your storage stay cold, and your protocols stay effective.
In a 4-year CV outcomes trial (Trial 7), 4,825 patients were randomized to RYBELSUS for a median follow-up of 49.6 months and 4,825 patients were randomized to placebo for a median follow-up of 49.4 months [see Clinical Studies (14.4)]
Additionally, the recent VIIH database analysis showed significant improvements in headache outcomes with GLP-1 RA therapy, with 76.9% of patients achieving 50% reduction in monthly headache days [68]
The incidence and the prevalence of IIH have been rising in parallel with the global obesity epidemic, reaching about 22 per 100,000 in obese young women [2, 3]
Nutrition guidance helps patients eat smarter